Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Palliative Care | 12 | 2022 | 3478 | 1.020 |
Why?
|
| Goals | 1 | 2022 | 705 | 0.580 |
Why?
|
| Radiation Oncology | 3 | 2018 | 554 | 0.550 |
Why?
|
| Bone Neoplasms | 3 | 2017 | 2522 | 0.490 |
Why?
|
| Spinal Neoplasms | 2 | 2018 | 759 | 0.470 |
Why?
|
| Cancer Care Facilities | 1 | 2016 | 401 | 0.440 |
Why?
|
| Pain Measurement | 1 | 2020 | 3418 | 0.380 |
Why?
|
| Benzopyrans | 1 | 2009 | 65 | 0.340 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2009 | 452 | 0.300 |
Why?
|
| Pain | 2 | 2022 | 4961 | 0.280 |
Why?
|
| Curcumin | 3 | 2012 | 95 | 0.270 |
Why?
|
| Mortality | 1 | 2017 | 2857 | 0.270 |
Why?
|
| Radiotherapy | 3 | 2017 | 1525 | 0.260 |
Why?
|
| Boronic Acids | 1 | 2009 | 965 | 0.250 |
Why?
|
| Qualitative Research | 3 | 2022 | 2680 | 0.240 |
Why?
|
| Nitriles | 1 | 2009 | 952 | 0.240 |
Why?
|
| Pyrazines | 1 | 2009 | 1231 | 0.220 |
Why?
|
| Endoplasmic Reticulum | 1 | 2009 | 1144 | 0.220 |
Why?
|
| Neoplasms | 6 | 2022 | 21596 | 0.210 |
Why?
|
| Lewy Body Disease | 1 | 2023 | 226 | 0.190 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 13019 | 0.190 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2012 | 358 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 7276 | 0.160 |
Why?
|
| Thioredoxin Reductase 1 | 3 | 2012 | 31 | 0.140 |
Why?
|
| Spinal Fractures | 1 | 2018 | 698 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 11039 | 0.100 |
Why?
|
| Joint Instability | 1 | 2018 | 792 | 0.090 |
Why?
|
| Nanocapsules | 1 | 2011 | 91 | 0.090 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2021 | 1631 | 0.090 |
Why?
|
| Radiation Tolerance | 1 | 2012 | 484 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 11472 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2023 | 3456 | 0.080 |
Why?
|
| Decision Making | 1 | 2021 | 3869 | 0.070 |
Why?
|
| Neurosurgical Procedures | 1 | 2017 | 2002 | 0.070 |
Why?
|
| Papillomaviridae | 1 | 2012 | 1118 | 0.070 |
Why?
|
| Humans | 21 | 2023 | 742088 | 0.070 |
Why?
|
| Patient Selection | 1 | 2018 | 4214 | 0.070 |
Why?
|
| Medulloblastoma | 1 | 2011 | 681 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2012 | 4029 | 0.060 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2011 | 806 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 790 | 0.060 |
Why?
|
| Radiosurgery | 1 | 2014 | 1309 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2009 | 1791 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2017 | 10248 | 0.060 |
Why?
|
| Aged | 8 | 2023 | 162944 | 0.060 |
Why?
|
| Quality of Life | 2 | 2022 | 12730 | 0.060 |
Why?
|
| Male | 9 | 2023 | 349538 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 57683 | 0.060 |
Why?
|
| Prognosis | 2 | 2022 | 29010 | 0.060 |
Why?
|
| Antineoplastic Agents | 3 | 2012 | 13655 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 5249 | 0.060 |
Why?
|
| Lewy Bodies | 1 | 2023 | 133 | 0.060 |
Why?
|
| Middle Aged | 8 | 2021 | 213127 | 0.050 |
Why?
|
| Endometrial Neoplasms | 1 | 2011 | 1351 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2020 | 53187 | 0.050 |
Why?
|
| Female | 9 | 2021 | 379592 | 0.050 |
Why?
|
| Giant Cells | 1 | 2021 | 187 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2021 | 4839 | 0.040 |
Why?
|
| Adult | 5 | 2020 | 213712 | 0.040 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2009 | 1377 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2012 | 2712 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 3800 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 8829 | 0.040 |
Why?
|
| Cultural Characteristics | 1 | 2019 | 262 | 0.040 |
Why?
|
| Death | 1 | 2022 | 675 | 0.040 |
Why?
|
| Referral and Consultation | 2 | 2020 | 3527 | 0.040 |
Why?
|
| Osteoclasts | 1 | 2021 | 729 | 0.040 |
Why?
|
| Morals | 1 | 2019 | 282 | 0.030 |
Why?
|
| Glioma | 1 | 2011 | 3388 | 0.030 |
Why?
|
| Spirituality | 1 | 2019 | 405 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2011 | 12695 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2019 | 921 | 0.030 |
Why?
|
| Patient Participation | 1 | 2021 | 1445 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 2876 | 0.020 |
Why?
|
| Spine | 1 | 2018 | 1143 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2012 | 319 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2017 | 2451 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2011 | 23387 | 0.020 |
Why?
|
| Solubility | 1 | 2011 | 1083 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2011 | 390 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2010 | 480 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2010 | 489 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2022 | 77098 | 0.020 |
Why?
|
| Orthopedic Procedures | 1 | 2018 | 1288 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 3215 | 0.020 |
Why?
|
| Communication | 1 | 2021 | 3728 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 1769 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 2885 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2012 | 3689 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 7770 | 0.020 |
Why?
|
| Sex Factors | 1 | 2019 | 10392 | 0.020 |
Why?
|
| Terminal Care | 1 | 2017 | 1688 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2010 | 1655 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2012 | 16665 | 0.020 |
Why?
|
| Massachusetts | 1 | 2017 | 8662 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2010 | 3701 | 0.010 |
Why?
|
| Polymers | 1 | 2011 | 1618 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2010 | 3127 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2011 | 2260 | 0.010 |
Why?
|
| Body Composition | 1 | 2011 | 2400 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 2077 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2011 | 6452 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2011 | 4024 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 2940 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 2723 | 0.010 |
Why?
|
| Peptides | 1 | 2011 | 4392 | 0.010 |
Why?
|
| Brain | 1 | 2023 | 26343 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2018 | 23320 | 0.010 |
Why?
|
| Animals | 3 | 2014 | 168561 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 9715 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 18006 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 56350 | 0.010 |
Why?
|
| United States | 1 | 2017 | 69693 | 0.010 |
Why?
|
| Obesity | 1 | 2011 | 12705 | 0.010 |
Why?
|
| Mice | 1 | 2012 | 81045 | 0.000 |
Why?
|
Concepts
(115)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(26)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_